A PHASE II STUDY OF FIRST-LINE BORTEZOMIB (B) IN PATIENTS (PTS) WITH STAGE IIIB/IV NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Planchard, D. [1 ]
Besse, B. [2 ]
Meric, J. B. [3 ]
Veillard, A. S. [1 ]
Pignon, J. P. [1 ]
Chan, K. [4 ]
Mathiot, C. [5 ]
Lumbroso, J. [1 ]
Lafontaine, C. [1 ]
Soria, J. C. [1 ]
机构：
[1] Inst Gustave Roussy, Dept Med, Villejuif, France
[2] Inst Gustave Roussy, Serv Med Gard, Villejuif, France
[3] Hop La Pitie Salpetriere, Dept Med Oncol, Paris, France
[4] Johnson & Johnson, Dept Oncol, High Wycombe, Bucks, England
[5] Inst Curie, Paris, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC)
    Smit, Egbert F.
    Dingemans, Anne-Marie C.
    Groen, Harry J.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S411 - S411
  • [2] A phase II study of eirlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC)
    Dingemans, A.
    Groen, H. J. M.
    Smit, E. F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 360 - 360
  • [3] A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).
    Suzuki, R
    Hasegawa, Y
    Baba, K
    Saka, H
    Saito, H
    Taniguchi, H
    Yamamoto, M
    Matsumoto, S
    Kato, K
    Shimokata, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
  • [4] A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS)
    Besse, B.
    Smit, E. F.
    Felip, E.
    Siena, S.
    Blackhall, F.
    Barlesi, F.
    Giaccone, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] FIRST-LINE ERLOTINIB IN STAGE IIIB/IV NON-SMALL-CELL LUNG CANCER (NSCLC) WITH DOSE ESCALATION TO TOXICITY IN CURRENT AND FORMER SMOKERS (C/FS): A PHASE II STUDY
    Besse, B.
    Smit, E.
    Felip, E.
    Siena, S.
    Blackhall, F.
    Barlesi, F.
    Giaccone, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 101 - 101
  • [6] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [7] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC)
    Groen, H. J.
    Smit, E. F.
    Dingemans, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Berge, Eamon M.
    Doebele, Robert C.
    Ballas, Marc S.
    Jahan, Thierry
    Haigentz, Missak, Jr.
    Hoffman, David
    Spicer, James
    West, Howard
    Lee, Pablo
    Yang, Ling
    Joshi, Adarsh
    Gao, Ling
    Yurasov, Sergey
    Mita, Alain
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1532 - 1539
  • [9] Weekly Regimen of Paclitaxel and Carboplatin as First-Line Chemotherapy in Elderly Patients with Stage IIIB-IV Non Small Cell Lung Cancer (NSCLC): Results of a Phase II Study
    Rozzi, A.
    Nardoni, C.
    Corona, M.
    Restuccia, M. R.
    Falbo, T.
    Lanzetta, G.
    JOURNAL OF CHEMOTHERAPY, 2010, 22 (06) : 419 - 423
  • [10] A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
    Suzuki, R.
    Hasegawa, Y.
    Baba, K.
    Saka, H.
    Saito, H.
    Taniguchi, H.
    Yamamoto, M.
    Matsumoto, S.
    Kato, K.
    Oishi, T.
    Imaizumi, K.
    Shimokata, K.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1599 - 1603
12345